Medical articles having enhanced therapeutic agent binding

• US 20070110786A1
• Filed: 11/15/2005
• Published: 05/17/2007
• Est. Priority Date: 11/15/2005
• Status: Abandoned Application

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Inventors: Tenney, Barron, Helmus, Michael
• Application Number:
  US11/274,538
• Publication Number:
  US 20070110786A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 47/59 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61L 2300/80 characterised by a special chemical form
• CPC Class Codes: A61L 2400/12 Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

According to an aspect of the present invention, medical articles are provided which comprise the following (a) a polymeric region having a first charge, and (b) a charged therapeutic agent having a second charge that is opposite in sign to that of the first charge. In certain beneficial embodiments, the medical articles are high surface area articles, for example, articles formed using small diameter (e.g., 10 microns or less) fibers.

Claims

1. A medical article comprising (a) a fiber having a diameter of 10 microns or less, said fiber comprising a polymeric region having a first charge, and (b) a charged therapeutic agent having a second charge that is opposite in sign to that of said first charge that is bound to said fiber.

2. The medical article of claim 1, wherein said medical article comprises a plurality of fibers.

3. The medical article of claim 1, wherein said fiber comprises a plurality of polymeric regions.

4. The medical article of claim 1, wherein a plurality of different charged therapeutic agents are bound to said fiber.

5. The medical article of claim 1, wherein said polymeric region extends throughout the diameter of said fiber.

6. The medical article of claim 1, wherein said polymeric region is a coating layer.

7. The medical article of claim 1, wherein said polymeric region comprises a nanotextured surface.

8. The medical article of claim 1, wherein said polymeric region has a critical surface energy between 20 and 30 dynes/cm.

9. The medical article of claim 1, wherein polymers make up 75% or more of said polymeric region.

10. The medical article of claim 1, wherein said fiber has a diameter between 10 nm and 10 microns.

11. The medical article of claim 1, wherein said first charge is a positive charge and said second charge is a negative charge.

12. The medical article of claim 11, wherein said charged therapeutic agent is DNA.

13. The medical article of claim 1, wherein said first charge is a negative charge and said second charge is a positive charge.

14. The medical article of claim 13, wherein said therapeutic agent is selected from amiloride, digoxin, morphine, procainamide, and quinine.

15. The medical article of claim 1, wherein said polymeric region comprises a polyionic polymer.

16. The medical article of claim 15, wherein said polyionic polymer is a polycationic polymer.

17. The medical article of claim 15, wherein said polyionic polymer is a polyanionic polymer.

18. The medical article of claim 1, wherein a charged species having said first charge is covalently attached to a surface of said polymeric region.

19. The medical article of claim 18, wherein said charged species is linked to said polymeric region using a linking agent.

20. The medical article of claim 18, wherein said charged species is provided by chemical treatment.

21. The medical article of claim 20, wherein said polymeric region is treated with an oxidizing or reducing agent.

22. The medical article of claim 20, wherein said surface comprises sulfonate groups.

23. The medical article of claim 20, wherein said chemical treatment comprises plasma treatment in the presence of a reactive gas.

24. The medical article of claim 23, wherein said gas comprises oxygen, carbon monoxide, carbon dioxide, ammonia, a mixture of molecular hydrogen and molecular nitrogen, or an amine.

25. The medical article of claim 23, wherein said gas comprises an unsaturated species that further comprises an acidic or basic functional group.

26. The medical article of claim 1, wherein a charged species having said first charge is non-covalently linked to a surface of said polymeric region.

27. The medical article of claim 1, wherein said charged therapeutic agent is selected from a therapeutic agent that is inherently charged, a therapeutic agent that is covalently attached to a charged molecule, a therapeutic agent that is non-covalently attached to a charged molecule, a therapeutic agent that is attached to or encapsulated within a charged particle, and a combination thereof.

28. The medical article of claim 1, wherein the polymeric region comprises a copolymer that comprises styrene and isobutylene.

29. The medical article of claim 28, wherein the copolymer comprises a polyisobutylene block and a polystyrene block.

30. The medical article of claim 28, wherein the copolymer is a polystyrene-polyisobutylene-polystyrene triblock copolymer.

31. The medical article of claim 28, wherein the copolymer is sulfonated.

32. The medical article of claim 28, wherein said medical article comprises a woven region comprising said fiber.

33. The medical article of claim 1, wherein said medical article comprises a non-woven region comprising said fiber.

34. The medical article of claim 1, wherein said medical article is a porous, tubular medical article.

35. The medical article of claim 1, wherein said medical article is selected from hollow fibers for oxygenators, hernia repair patches, gastrointestinal tract patches, uro-gynecological tract patches, vascular access ports, fabric to join devices to human arteries, wound dressings, membranes, anterior cruciate ligaments, neurovascular aneurysm treatment articles, valve leaflets for heart valves, valve leaflets for venous valves, stents, stent grafts, gastrointestinal tract grafts, uro-gynecological tract grafts, coronary vascular grafts, peripheral vascular grafts, arterio-venous access grafts, embolic filters, and scaffolds for tissue engineering.

36. The medical article of claim 1, wherein said medical article comprises a region comprising said fiber, disposed over an underlying medical device substrate.

37. The medical article of claim 36, wherein said medical device substrate is a metallic stent.